BioCentury
ARTICLE | Clinical News

Acceleron's dalantercept fails in Phase II RCC trial

June 12, 2017 11:41 PM UTC

Acceleron Pharma Inc. (NASDAQ:XLRN) said it is discontinuing development of dalantercept (ACE-041) after the candidate missed the primary endpoint in the Phase II DART study to treat advanced renal cell carcinoma. Among 119 evaluable patients, dalantercept failed to significantly improve median progression-free survival (PFS) vs. placebo (6.8 vs. 5.6 months, HR=1.11, two-sided 95% CI: 0.71, 1.73, one-sided p=0.67).

The trial compared dalantercept plus Inlyta axitinib with placebo plus Inlyta in patients who have progressed following treatment with a VEGF receptor tyrosine kinase inhibitor. Dalantercept is an angiogenesis inhibitor that binds to and prevents members of the transforming growth factor (TGF) beta superfamily from signaling through activin receptor-like kinase 1 (ACVRL1; ALK1; HHT2)...